Sign in Subscribe

Archive

A collection of 715 issues

Latest

Practical management guidance for BRAF V600E-mutated mCRC in the post-BREAKWATER era

Skip to content The CRC Digest Practical management guidance for BRAF V600E-mutated mCRC in the post-BREAKWATER era A narrative review evaluates clinical integration of BRAF-targeted therapy combined with EGFR inhibition, addressing first-line treatment, MMR/MSI status, patient fitness, and sequencing strategies. (J Gastrointest Cancer) This content is informational only and

Single colonoscopy screening invitation reduces colorectal cancer incidence but not mortality at 13 years

Skip to content The CRC Digest ▪ SCREENING Single colonoscopy screening invitation reduces colorectal cancer incidence but not mortality at 13 years A long-term study found that a single colonoscopy screening invitation reduced CRC incidence compared to no invitation, but did not reduce cancer-related mortality at 13-year follow-up. (Ann Intern Med)

Discoidin Domain Receptor 1 promotes collagen alignment and immune exclusion in microsatellite stable colorectal cancer

Skip to content The CRC Digest ◇ RESEARCH Discoidin Domain Receptor 1 promotes collagen alignment and immune exclusion in microsatellite stable colorectal cancer (Cancer Res Commun) This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The CRC Digest — crcdigest.com

High-dose vitamin D3 does not improve progression-free survival in metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA High-dose vitamin D3 does not improve progression-free survival in metastatic colorectal cancer The phase III SOLARIS trial found median PFS was 11.8 months with high-dose vitamin D3 (8,000 IU then 4,000 IU daily) versus 10.3 months with standard-dose

Oral TKI anlotinib shows non-inferiority to bevacizumab plus chemotherapy in first-line RAS/BRAF wild-type metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Oral TKI anlotinib shows non-inferiority to bevacizumab plus chemotherapy in first-line RAS/BRAF wild-type metastatic colorectal cancer The phase 3 ANCHOR trial (NCT04854668) compared CapeOX chemotherapy combined with anlotinib versus CapeOX combined with bevacizumab in patients with RAS/BRAF wild-type mCRC, evaluating

CRC Research Update — August 31, 2026

Today's colorectal cancer research highlights

Plant-derived formulation disrupts metabolism in KRAS-mutant colorectal and pancreatic cancer cells

Skip to content The CRC Digest Plant-derived formulation disrupts metabolism in KRAS-mutant colorectal and pancreatic cancer cells A Lepidium latifolium formulation induced cell death and metabolic disruption in KRAS-mutant cancer models through iron-dependent mechanisms. (Molecules) This content is informational only and does not constitute medical advice. Always consult your oncologist

Roadmap for early-onset colorectal cancer prevention highlights lifestyle factors and emerging risk pathways

Skip to content The CRC Digest Roadmap for early-onset colorectal cancer prevention highlights lifestyle factors and emerging risk pathways Review identifies obesity, metabolic conditions, poor diet, and sedentary behavior as key EOCRC risk factors, with growing evidence for early-life and gut microbial exposures. (Nature Reviews Cancer) This content is informational

Study evaluates potential hearing damage from oxaliplatin in preclinical model

Skip to content The CRC Digest ♥ LIVING WITH CRC Study evaluates potential hearing damage from oxaliplatin in preclinical model Mouse study evaluated potential hearing damage induced by oxaliplatin. (Hearing Research) This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The

NF-κB/Lipocalin 2 pathway may reduce chemoresistance in BRAF-mutant colorectal cancer by promoting ferroptosis

Skip to content The CRC Digest ◇ RESEARCH NF-κB/Lipocalin 2 pathway may reduce chemoresistance in BRAF-mutant colorectal cancer by promoting ferroptosis Preclinical research found that the NF-κB/LCN2 signaling pathway enhances cisplatin sensitivity in BRAF V600E-mutant CRC cells through iron-dependent cell death. (Cancers) This content is informational only and does